MaxCyte, Inc.

NasdaqGS:MXCT Stock Report

Market Cap: US$358.2m

MaxCyte Valuation

Is MXCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MXCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MXCT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MXCT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MXCT?

Key metric: As MXCT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MXCT. This is calculated by dividing MXCT's market cap by their current revenue.
What is MXCT's PS Ratio?
PS Ratio7.9x
SalesUS$45.60m
Market CapUS$358.20m

Price to Sales Ratio vs Peers

How does MXCT's PS Ratio compare to its peers?

The above table shows the PS ratio for MXCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.1x
CYRX Cryoport
1.4x7.5%US$322.3m
SLGC Standard BioTools
4.8x16.4%US$396.2m
QTRX Quanterix
3.5x14.4%US$449.8m
TKNO Alpha Teknova
10.8x14.1%US$388.1m
MXCT MaxCyte
7.9x20.5%US$285.9m

Price-To-Sales vs Peers: MXCT is expensive based on its Price-To-Sales Ratio (7.9x) compared to the peer average (5.1x).

Price to Sales Ratio vs Industry

How does MXCT's PS Ratio compare vs other companies in the US Life Sciences Industry?

10 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.6x2.4%US$1.75b
ATLN Atlantic International
0.6xn/aUS$253.24m
NOTV Inotiv
0.2x7.5%US$88.67m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
MXCT 7.9xIndustry Avg. 3.2xNo. of Companies10PS02.85.68.411.214+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MXCT is expensive based on its Price-To-Sales Ratio (7.9x) compared to the US Life Sciences industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is MXCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MXCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.9x
Fair PS Ratio4.6x

Price-To-Sales vs Fair Ratio: MXCT is expensive based on its Price-To-Sales Ratio (7.9x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MXCT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.55
US$8.20
+131.1%
20.3%US$9.87US$6.54n/a2
Nov ’25US$3.77
US$8.25
+118.9%
20.7%US$9.96US$6.54n/a2
Oct ’25US$3.70
US$6.97
+88.4%
39.8%US$9.74US$4.20n/a2
Sep ’25US$4.32
US$6.97
+61.4%
39.8%US$9.74US$4.20n/a2
Aug ’25US$4.57
US$6.99
+53.0%
40.8%US$9.85US$4.14n/a2
Jul ’25US$3.83
US$6.91
+80.4%
40.1%US$9.68US$4.14n/a2
Jun ’25US$4.48
US$6.94
+55.0%
40.4%US$9.75US$4.14n/a2
Oct ’24US$3.12
US$9.39
+201.0%
6.5%US$10.00US$8.78US$3.702
Sep ’24US$3.70
US$9.39
+153.8%
6.5%US$10.00US$8.78US$4.322
Aug ’24US$4.50
US$10.76
+139.2%
7.0%US$11.51US$10.02US$4.572
Jul ’24US$4.59
US$10.70
+133.1%
7.6%US$11.51US$9.89US$3.832
Jun ’24US$4.14
US$10.67
+157.8%
7.8%US$11.51US$9.84US$4.482
May ’24US$4.85
US$12.05
+148.5%
6.5%US$12.84US$11.27US$3.782
Apr ’24US$4.95
US$12.05
+143.5%
6.5%US$12.84US$11.27US$4.192
Mar ’24US$4.43
US$11.98
+170.4%
3.2%US$12.36US$11.60US$4.712
Feb ’24US$5.69
US$11.98
+110.6%
3.2%US$12.36US$11.60US$5.192
Jan ’24US$5.46
US$12.06
+120.8%
2.5%US$12.36US$11.75US$4.702
Dec ’23US$6.17
US$11.93
+93.3%
3.6%US$12.36US$11.49US$4.982
Nov ’23US$6.89
US$11.66
+69.2%
11.1%US$12.95US$10.37US$3.282

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Collegium Pharmaceutical

US$980.7m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

1.3%

1Y

15.1%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

0.6%

1Y

9.8%